Traws Pharma, Inc.
TRAWDrugs in Pipeline
9
Phase 3 Programs
3
Upcoming Catalysts
1
Next Catalyst
Dec 15, 2026
37wMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
rigosertib sodium
Myelodysplastic Syndromes
ON 01910.Na
Myelodysplastic Syndrome
Gemcitabine
Metastatic Pancreatic Adenocarcinoma
rigosertib
Head and Neck Squamous Cell Carcinoma
Narazaciclib
Endometrioid Endometrial Cancer
Oral rigosertib
Myelodysplastic Syndromes
TRX-100
Influenza
Ratutrelvir (83-0060) non-randomised
COVID - 19
Azacitidine
Myelodysplastic Syndrome
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
rigosertib sodium | Phase 3 | Myelodysplastic Syndromes | - | - |
ON 01910.Na | Phase 3 | Myelodysplastic Syndrome | - | - |
Gemcitabine | Phase 3 | Metastatic Pancreatic Adenocarcinoma | - | |
rigosertib | Phase 2 | Head and Neck Squamous Cell Carcinoma | - | - |
Narazaciclib | Phase 2 | Endometrioid Endometrial Cancer | - | - |
Oral rigosertib | Phase 2 | Myelodysplastic Syndromes | - | - |
TRX-100 | Phase 2 | Influenza | - | - |
Ratutrelvir (83-0060) non-randomised | Phase 2 | COVID - 19 | - | - |
Azacitidine | Phase 2 | Myelodysplastic Syndrome | - |
Myelodysplastic Syndromes
2 drugs in this indication
Myelodysplastic Syndrome
2 drugs in this indication
Metastatic Pancreatic Adenocarcinoma
1 drug in this indication
COVID - 19
1 drug in this indication
Endometrioid Endometrial Cancer
1 drug in this indication
Head and Neck Squamous Cell Carcinoma
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)